Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad-EndoAngio
- Development stage
- Preclinical
- Modality
- Gene Therapies, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intratumoral
01
Overview
Ad-EndoAngio is a non-replicating adenoviral gene therapy vector designed to express a fusion protein of endostatin and angiostatin. Endostatin and angiostatin are endogenous inhibitors of angiogenesis that work synergistically to suppress tumor vascularization. By delivering the genes for these proteins directly into the tumor environment, Ad-EndoAngio provides sustained anti-angiogenic activity, which has been shown in preclinical models to significantly inhibit the growth and metastasis of renal cell carcinoma (RCC). The therapy aims to exploit the highly vascular nature of RCC to starve the tumor of its blood supply.
- Other names
- Adenoviral endostatin-angiostatin fusion proteinEndoAngio gene therapy
Beyond the preview
Go deeper on Ad-EndoAngio.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad-EndoAngio.